Please login to the form below

Not currently logged in
Email:
Password:

Quintiles acquires US CRO Novella Clinical

Deal will boost its small biopharma, oncology and medical device capabilities

Pharmaceutical services company Quintiles has bolstered its contract research capabilities with the acquisition of Novella Clinical for an undisclosed amount.

The US-headquartered contract research organisation (CRO) has more than 800 employees across North America and Europe and focuses on oncology, medical devices and diagnostics sectors

Quintiles, which said the deal would help it stay ahead of the diverse and evolving needs of its global customer base, also expects a boost for its small biopharma capabilities.

Paula Brown Stafford, president, clinical development at Quintiles, said: “The expertise and insight the Novella team brings will be a strong addition to our existing capabilities and help further differentiate Quintiles in an increasingly competitive marketplace.

“Novella's understanding of emerging companies, as well as our shared commitment to quality, customer service, and above all, the patients we ultimately serve, makes this acquisition a good fit for both organisations.”

Founded 15 years ago, Novella is a full-service CRO whose offerings include clinical monitoring, data management, regulatory affairs, qualify assurance and safety management.

Once the acquisition is completed Novella will operate as a standalone unit within Quintiles under its existing name.

23rd August 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics